European approval of INTERCEPT Blood System for plasma triggered the award.

Cerus received a $5-million cash milestone payment from BioOne triggered by the CE mark regulatory approval for its INTERCEPT Blood System for plasma in Europe. The agreements between Cerus and BioOne provide for milestone payments to Cerus as well as royalties based on sales of the INTERCEPT Blood System for platelets and plasma.

Cerus also expects an addition payment of BioOne preferred stock worth $5 million in early 2007. Upon receipt of the cash milestone payment, Cerus forwarded $0.5 million to Baxter Healthcare according to an agreement relating to the BioOne commercialization rights.

Previous articleSanofi-Aventis Obtains Expanded Access to ImmunoGen’s TAP Technology
Next articleEpiCept Licenses Back Pain-Related Patent to Durect